For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 20,294 | 10,145* | 10,525 | 13,124 |
| General and administrative | 6,844 | 5,769* | 4,426 | 5,558 |
| Total operating expenses | 27,138 | 15,914 | 14,951 | 18,682 |
| Loss from operations | -27,138 | -15,914* | -14,951 | -18,682 |
| Interest income | 1,561 | 1,781* | 1,532 | 1,683 |
| Interest expense | 545 | 525* | 650 | 646 |
| Loss on debt extinguishment | 0 | -681* | 0 | 0 |
| Other, net | 115 | 68* | 112 | 61 |
| Total other income, net | 901 | 507* | 770 | 976 |
| Net loss | -26,237 | -15,407 | -14,181 | -17,706 |
| Basic EPS | -0.8 | -0.476 | -0.52 | -0.65 |
| Diluted EPS | -0.8 | -0.476 | -0.52 | -0.65 |
| Basic Average Shares | 32,893,000 | 32,380,000 | 27,104,000 | 27,072,000 |
| Diluted Average Shares | 32,893,000 | 32,380,000 | 27,104,000 | 27,072,000 |
Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (ANRO)